ArticleNature2026
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance.
Abstract read
In one paragraph
Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Advances in Bispecific Antibodies and Antibody-Drug Conjugates for Colorectal Cancer Treatment.Antibodies (Basel, Switzerland) · 2026Review
- Cystic Fibrosis and Colorectal Cancer Risk: Reprogramming of the Intestinal Epithelial Niche and Cell-State Plasticity in the CFTR Modulator Era.Cell proliferation · 2026Review
- Article
- Impact of non-genetic heterogeneity of BRAF-mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics.International journal of cancer · 2026Article
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Cancer cell · 2026Article
- Progressive intestinal tumor cell plasticity, Myc activation, and loss of Lgr5Science advances · 2026Article
- Article
- Multidrug resistance in cancer: current understandings and future perspective.Molecular biomedicine · 2026Review
- The integrated clinico-scientific system for gastrointestinal diseases combining Chinese and Western medicine.Journal of translational medicine · 2026Article
- LGR5: from stem cell marker to therapeutic target.Trends in cancer · 2026Review
- Ras-MAPK inhibition induces AXIN1 loss in colorectal cancer by mTOR associated suppression of protein synthesis.Cell communication and signaling : CCS · 2026Article
- Functional Exploration of African Colorectal Cancer Patients Using PersonalisedbioRxiv : the preprint server for biology · 2026Article
- Engineered Bacteria-Vesicle Delivered Lactate Reprogramming Boosts Tumor Radiosensitivity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advances in CRISPR/Cas systems for engineering abiotic stress tolerance in plants: mechanisms and future prospects.Planta · 2026Review
- Oncofetal reprogramming and cellular plasticity in colorectal cancer: from mechanisms to clinical translation.Frontiers in oncology · 2026Review
- Identification of Drug-resistant Cell Subpopulations in Colorectal Cancer Through Single-cell Analysis and Exploration of Potential Therapeutic Strategies.Current medicinal chemistry · 2026Article
- Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors.
Mark White *Cancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-6309-3254
Megan L Mills *Cancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0000-0922-7912
Laura M Millett *Cancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0000-7596-4275
Kathryn GilroyCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-4607-194X
Yourae HongCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-6683-433X
Lucas B ZeigerCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-8712-3112
Rosalin J SimpsonCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0001-8571-7275
Shania M CorryWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Amelia LigezaWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0009-0006-9075-3138
Tamsin R M LannaganCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-8206-8898
Susanti SusantiCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-9704-5157
Rachel A RidgwayCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-0198-8244
Ayse S YazgiliCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-8485-9653
Lucile GrzesiakWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0002-7351-2045
Raheleh AmirkhahThe Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK.ORCID 0000-0003-3494-271X
Catriona A FordCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-3991-6369
Nikola VlahovCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0002-8649-6109
Hannah TovellCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-2473-7256
Leah Officer-JonesCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-3690-2386
Catherine FickenCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-4764-210X
Rachel PennieCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0001-4796-7388
Arafath K NajumudeenCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-3764-5721
Alexander RavenCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-4409-9543
Nadia NasreddinCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-3025-6213
Ekansh ChauhanCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-1096-0625
Andrew S PapanastasiouCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-8888-0633
Colin NixonCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-8085-2160
Vivienne MorrisonCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0009-0009-1022-8969
Rene JackstadtHeidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.ORCID 0009-0005-6246-2133
Janet S GrahamSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0002-2048-2698
Crispin J MillerCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-4341-1283
Sarah J RossOTD Bioscience, Early Oncology, AstraZeneca, Cambridge, UK.ORCID 0000-0001-8759-1728
Simon T BarryOTD Bioscience, Early Oncology, AstraZeneca, Cambridge, UK.ORCID 0000-0002-8511-0588
Valeria PavetCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0002-4472-6503
Richard H WilsonSchool of Cancer Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-8018-7730
John Le QuesneCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0003-3552-7446
Philip D DunneCancer Research UK Scotland Institute, Glasgow, UK.ORCID 0000-0001-9160-283X
Sabine TejparDigestive Oncology, Katholieke Universiteit Leuven, Leuven, Belgium.ORCID 0000-0003-3281-8643
Simon LeedhamWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.ORCID 0000-0003-1476-6982
Andrew D CampbellCancer Research UK Scotland Institute, Glasgow, UK. a.campbell@crukscotlandinstitute.ac.uk.ORCID 0000-0003-3930-1276
Owen J SansomCancer Research UK Scotland Institute, Glasgow, UK. o.sansom@crukscotlandinstitute.ac.uk.ORCID 0000-0001-9540-3010
Funding
Cancer Research UK core
Abstract
The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40-50%) and BRAF (10%)
Indexed as
Cell PlasticityColorectal NeoplasmsDrug Resistance, NeoplasmEpithelial CellsMAP Kinase Signaling SystemAnimalsCell Line, TumorErbB ReceptorsFemaleHumansMaleMiceMutationNeoplastic Stem CellsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafBRAF protein, humanErbB ReceptorsKRAS protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Ubiquitin-Protein Ligases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.